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Abstract
Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every year. As a
consequence, needs for cost control are often expressed. One possible solution for cost control could come
through increasing generic substitution by pharmacists. We aim to analyse the extent and nature of substitution in
recent years and estimate the likelihood of generic or branded substitution in Dutch pharmacies in relation to
various characteristics.
Methods: We utilized a linked prescription dataset originating from a general practitioner (GP) and a pharmacy
database, both from the northern Netherlands. We selected specific drugs of interest, containing about 55,000
prescriptions from 15 different classes. We used a crossed generalized linear mixed model to estimate the effects
that certain patient and pharmacy characteristics as well as timing have on the likelihood that a prescription will
eventually be substituted by the pharmacist.
Results: Generic substitution occurred at 25% of the branded prescriptions. Generic substitution was more likely to
occur earlier in time after patent expiry and to patients that were older and more experienced in their drug use.
Individually owned pharmacies had a lower probability of generic substitution compared to chain pharmacies.
Oppositely, branded substitution occurred in 10% of generic prescriptions and was positively related to the
patients’ experience in branded use. Individually owned pharmacies were more likely to substitute a generic drug
to a branded compared to other pharmacies. Antidepressant and PPI prescriptions were less prone to generic and
more prone to branded substitution.
Conclusion: Analysis of prescription substitution by the pharmacist revealed strong relations between substitution
and patient experience on drug use, pharmacy status and timing. These findings can be utilised to design further
strategies to enhance generic substitution.
Background
Despite the efforts of governments, insurance companies
and health care providers to enhance cost control, health
expenditures in the developed world rise every year. The
main reasons for this trend are the ageing of the popula-
tion, growing expectations regarding health by the society
as well as the continuous improvement in health technol-
ogies [1]. Expenditures on pharmaceuticals are responsi-
ble for a major share in health expenditures and the
percentage of pharmaceutical expenditures has been con-
stantly rising for the last 30 years [1]. The Netherlands
also faces the same trend of increasing health care and
pharmaceutical costs. Pharmaceutical costs however, if
expressed as a percentage of the total health expenditures
are much lower in the Netherlands, compared to other
major European economies such as Germany, UK and
France [2]. Possibly, the relatively strict regulatory policy
on the introduction and reimbursement of new drugs,
the restrictive prescription policies (for example, regard-
ing antibiotics) and the active stimulation of generic drug
use might all be related to this phenomenon.
In particular, the potentials for cost savings due to gen-
eric drug use has been recognized relatively early in the
Netherlands, where in 1988 already about a quarter of
the prescriptions were prescribed using the generic name
[3]. The Dutch government, in its effort to contain costs,
would stimulate generic use through generic substitution;
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a branded drug is indicated on the GP prescription.
Although generic substitution was already allowed,
provided that the pharmacist would first consult the pre-
scriber, in 1998 the Dutch law stimulated generic substi-
tution further by relaxing this compulsory consultation.
Nowadays, the Netherlands belongs to the group of
countries with the highest proportion of generic use,
w i t ham a r k e tv o l u m eo fg e n e r i cd r u g ss l i g h t l ya b o v e
50% of the total national drug volume [4].
The reasons for a pharmacist to embark on generic
substitution vary, but might (partly) be related to finan-
cial considerations within the private pharmacist’so w n
business and an awareness to enhance cost control in
general. In particular, a pharmacist may dispense the
generic instead of the branded drug because:
￿ at least until 2000, the pharmacist gained more
profit through discounts offered from manufacturers
of generic rather than of branded drugs [5];
￿ until 2003, a law aiming to stimulate generic use
allowed the pharmacist to keep one third of the dif-
ference between the reference and actual price of
the dispensed drug;
￿ t h e r ei sn oa v a i l a b l es t o c ko ft h eb r a n d e dp r o d u c t
at the pharmacy;
￿ the pharmacist behaves cost consciously and is
willing to adhere to governmental regulations and
public preferences; and
￿ a branded prescription may not be (fully) reim-
bursed by the insurance company if the generic
alternative is a lot cheaper, especially if there is a
specific policy from the insurance company towards
generics (for example, a preference policy regarding
several drug classes has been endorsed by various
insurance companies in the Netherlands).
Yet, despite the pressure of the government and the
insurance companies on the broader use of generic drugs,
the pharmaceutical expenditures in the Netherlands are
still increasing [6]. One reason for this phenomenon is the
relatively high level at which the producers still set the
generic prices. Also, during the last years an increasing
number of new branded drugs entered the pharmaceutical
market, increasing the potentials for alternative means of
treatment, branded prescribing and substitution between
brands [7]. According to Gumbs et al [8], the Dutch
society could benefit with a health expenditure reduction
of 71 million Euros if branded statin prescribing would be
generically substituted in current users who are eligible for
receiving generic treatment. Finally, in daily pharmacy
practice, branded substitution is sometimes observed,
where a generic prescription is being filled with the
branded drug. Reasons for this include the level of severity
of the disease, the personal preferences of the patient, the
financial profit of the pharmacist as well as existing or per-
ceived adverse effects related to generics in specific disease
types [9].
Although stimulation of generic substitution in the
Netherlands was initiated already more than a decade
ago, little has been published regarding its frequency in
daily practice. The aim of this study was to analyse the
extent of generic and branded substitution for a number
of popular drug classes in the northern Netherlands and
subsequently to quantify the effect that several patient
and pharmacist characteristics, as well as the timing of
prescriptions had on the likelihood of generic or branded
substitution by the pharmacist.
Methods
Data Source
The dataset for the analyses was established after linking
prescriptions from databases on GP prescribing and phar-
macy delivering, for a set of different drug classes (each
class containing one branded and one or more generic
drugs of the same chemical entity). We selected drug
classes from the four most prescribed drug groups in the
Netherlands (statins, angiotensin-converting enzyme
(ACE) inhibitors, proton pump inhibitors (PPIs) and anti-
depressants), where also at least one generic was available.
Furthermore, we selected drug classes where the branded
drug’s patent expiry occurred within the period for which
the linked databases could provide sufficient information,
both prior and post expiry. Table 1 shows the drugs that
were included, using these selection criteria.
GP prescriptions were collected from the Registration
Network Groningen (RNG) database [10,11], while the
pharmacy dispensing information was collected from
IADB.nl [12].
RNG has an annual average population size of about
30,000 patients. The RNG comprises three practices in
the northern Netherlands and a total number of 17 parti-
cipating GPs. All GPs routinely register the patient data
electronically through a specific software package. Within
the registered information, for example, date of entry to
the practice, exit data (if applicable) and dates of visits
are recorded, enabling analyses where person-based
tracking in time is necessary, such as calculations of rates
of presence and occurrence of episodes, disease and pre-
scriptions (prevalence and incidence).
IADB.nl comprises the full populations of the main
cities and some regional centers in the north of the
Netherlands. The adherent population of IADB.nl is
approximately 500,000 persons. The database was most
recently updated to include prescription/dispensing data
up to and including 01-01-2007.
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For the selected drugs, data on prescribing and dispen-
sing were selected from RNG and IADB.nl from the time
of patent expiry of each drug until the end of the last
update of IADB.nl (01-01-2007). These data were subse-
quently linked to each other. The linking of the two data-
sets was based on the personal information of the
patients (postal code, gender and date of birth). Thus,
patients were matched in both databases on the basis of
their date of birth, their gender and finally their postal
code of residence. The linking procedure was performed
under strict privacy rules and patient anonymity was
ensured for the researchers involved. The combinations
of these characteristics, together with the exact informa-
tion on the Anatomic Therapeutic Chemical (ATC) code,
enabled the identification of 96% of the RNG patients in
IADB.nl.
Variables Investigated
Through the linking procedure described above we
obtained information on the drug type (branded or gen-
eric) that was initially prescribed and the type that was
finally dispensed, linked with different patient and phar-
macy characteristics as well as on information regarding
the exact timing of the prescription.
The outcome studied was whether a prescription filled
with the branded (generic) name by the GP was substi-
tuted with the generic (branded) during delivery from
the pharmacist.
Past research has shown that the decision of generic
or branded substitution can be influenced by drug price,
drug class and patient, pharmacy and insurance com-
pany characteristics [7]. Here, we assumed that price
should not be included as an explanatory characteristic
in our analysis since copayment was not necessary for
any of the studied drugs, and therefore the patient
doesn’t really notice the exact price level. Information
regarding the additional profit that pharmacists might
have gained through relevant discounts offered during
the wholesaling process, although potentially relevant,
was not included in the analysis as no data on this was
available, neither in the linked dataset, nor outside of it.
Further, since health insurance is compulsory in the
Netherlands and all prescriptions were fully reimbursed
by all health insurances, we did not investigate different
substitution patterns among prescriptions potentially
caused by different health insurance schemes. Therefore,
for every prescription in the database we collected the
following explanatory variables:
￿ A categorical variable indicating the drug group of
the prescription (ACE inhibitors, antidepressants,
PPIs or statins);
￿ A binary variable capturing whether a patient was
female or male;
￿ The age of the patient at the time of generic/
branded substitution (divided in four quantiles);
￿ A binary variable defining whether the prescription
referred to the patient’s first prescription from the
specific drug class;
￿ A variable capturing the prescription history of a
patient, defined as the number of all prescriptions
from the specific drug class in the last six months;
￿ A variable capturing the patient’s ratio of branded
versus all prescriptions for the specific drug class in
the last six months;
￿ A categorical variable capturing the pharmacy
ownership status and distinguishing between:
○ an individually owned pharmacy;
○ a pharmacy belonging (among other pharma-
cies) to a multiple pharmacies’ owner;
○ a pharmacy belonging to a partnership; and
○ a pharmacy belonging to a pharmacy chain;
￿ The duration after patent expiry (in months); i.e.
the time between patent expiry and the specific pre-
scription considered.
Statistical Analysis
A Generalized Linear Mixed Model (GLMM) with
crossed random effects [13-15] was applied in order to
model the effect of the independent variables on the
likelihood of generic and branded substitution by the
Table 1 Drug groups included in the analysis, branded
manufacturers between brackets and patent expiry dates
Drug name Branded drug Patent expiry date
a
ACE Inhibitors
Enalapril Renitec
® [MSD] 13-12-1999
Lisinopril Zestril
® [AstraZeneca] 8-10-2002
Ramipril Tritace
® [Sanofi-Aventis] 13-1-2004
Quinapril Acupril
® [Pfizer] 5-10-2004
Fosinopril Newace
® [BMS] 4-7-2005
Antidepressants
Fluoxetine Prozac
® [Eli Lilly] 14-12-1999
Paroxetine Seroxat
® [GSK] 12-7-2001
Citalopram Cipramil
® [Lundbeck] 1-2-2002
Moclobemide Aurorix
® [Roche] 4-4-2002
Mirtrazapine Remeron
® [Shering-Plough] 13-9-2004
Sertraline Zoloft
® [Pfizer] 28-10-2005
PPIs
Omperazol Losec
® [AstraZeneca] 18-4-2002
Lansoprazol Prezal
® [Sanofi-Aventis] 19-12-2005
Statins
Simvastatine Zocor
® [MSD] 1-5-2003
Pravastatine Selektine
® [BMS] 2-8-2004
a Defined as the date of the first prescription encountered in IADB.nl.
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with prescriptions originating from 4,417 different
patients and 26 different pharmacies, necessitated the
use of a multilevel, random effect approach in the mod-
eling of the covariates’ effects. Random effects accounted
for the fact that prescriptions with the same observable
independent factors, but filled by different pharmacies
(yet, of the same ownership status) or referring to differ-
ent patients (yet of the same age category and sex), may
have different probabilities of being substituted. Further-
more, the non-nested structure of the random effects
(since every patient can logically pick up drugs from
various pharmacies) urged the use of an approach which
would allow us to include patients and pharmacists as
crossed independent random effects. Hence, for the i
th
time that the j
th individual received a drug from the k
th
drug class by the l
th pharmacy, we defined the binary
responses:
yijkl =
⎧
⎪ ⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎪ ⎩
1 for generic delivery of
a branded prescription,
0 for branded delivery of
a branded prescritpion,
and
hijkl =
⎧
⎪ ⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎪ ⎩
1 for branded delivery of
a generic prescription,
0 for generic delivery of
a generic prescritpion.
By denoting this in terms of probabilities (Pr) - in par-
ticular, πijkl =P r ( yijkl =1 )a n dξijkl =P r ( hijkl =1 )-t h e
models for generic and branded substitution can be for-
mulated as
log
 
πijkl
1-πijkl
 
= XT
ijklβ + αj + ul (1)
log
 
ξijkl
1-ξijkl
 
= ZT
ijklγ + δj + el (2)
Where Xijkl and Zijkl contain the independent covari-
ates used in both specifications, b and g are the fixed
effect parameters and aj, δj and ul,, el the patient and
pharmacist random effects parameters, respectively. In
order for equations (1) and (2) to be identifiable we
assumed that each random effects parameter follows a
normal distribution with mean zero and variance sa, sδ,
su and se respectively.
The assumption of normality for the two random
effect parameters was tested with the help of QQ plots
and the Shapiro-Wilk normality test [16]. Comparison
among models with different covariate sets was based
on likelihood ratio tests (LRT) [17]. The Somers’ Dxy
criterion, a transformation of the level of concordance
criterion, was calculated for every model to further
assess the goodness of the model fit [18]. The closer the
value of Dxy was to one, the better the fit of the model
was. Finally, the Cook’sd i s t a n c ef o rG L M M sw a se s t i -
mated in order to check the influence of the individual
components of the random effects (pharmacies or
patients) on the parameter estimates [19]. In particular,
components whose Cook’s distance value exceeded that
of 4/n (n being the number of individual components
within every random effect) were considered to be influ-
encing the model estimates more strongly than should
be expected [20].
For the estimation of the GLMM we used the package
“lme4” from the freely available statistical software R
(version 2.10.0) [21,22].
Results
Subject Characteristics
The linked prescription data consisted of 53,899 pre-
scriptions originating from 4,417 subjects. Of these pre-
scriptions 36,695 (68.1%) were generically prescribed by
the GP. From the rest 17,204 (31.9%) branded prescrip-
tions, 4,292 were generically substituted by the pharma-
cist; i.e. 24.9% of branded was generically substituted.
Also, out of all generic prescriptions 3,664 (10%) were
filled with a branded drug by the pharmacist (Figure 1).
Table 2 presents the characteristics of the prescrip-
tions used in the branded and generic substitution ana-
lysis, respectively.
GLMM results for generic substitution
The estimates of the applied GLMMs on the probability
of generic and branded substitution are presented in
Table 3. The fixed effects estimates indicate that the
probability of generic substitution is negatively asso-
ciated with a high proportion of prior brand use (b’s
Figure 1 Number of linked prescriptions (pharmacy and GP
database) and percentages (between brackets) of branded -
generic prescribing.
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Page 4 of 9varying from -3.210 to -5.952, with P < 0.001 in both
cases; see Table 3) and receiving a prescription further
beyond the patent expiry date (b = -0.011, P =0 . 0 0 2 ) .I f
a prescription refers to a drug belonging to a drug class
that is prescribed for the first time to the patient, the
likelihood of generic substitution is smaller (b = -2.582,
P < 0.001). Being dispensed a prescription from a phar-
macy belonging to a partnership (b =0 . 9 5 4 ,P =0 . 0 4 6 )
or a chain (b =0 . 6 8 7 ,P< 0.001), to a patient having
more experience on the use of drugs from the specific
drug class (b = 0.076, P < 0.001) and being older than
the baseline age group are all positively associated with
the probability of generic substitution. Finally, prescrip-
tions referring to antidepressants or PPIs are less likely
to be generically substituted (b = -0.579, P = 0.004 and
b = -1.085, P< 0.001 respectively), compared to prescrip-
tions of ACE inhibitors. The opposite holds true for sta-
tins (b = 0.574, P = 0.001), again as compared to ACE
inhibitors.
The LRTs comparing the full model of Table 3 against
the reduced models, where each of the random effects are
removed gradually (not shown here), established the signif-
icance of both random terms. Hence, there is evidence that
the probability of generic substitution varies from patient
to patient and from pharmacy to pharmacy. The assump-
tion of normality of the random effect term was rejected
for both pharmacy and patient random effect terms (P <
0.001 for both SW tests). QQ plots (not shown here)
revealed that the distribution of the random effects was
leptokurtic (i.e more peaked around the mean) but concen-
trated around zero. This implies that the misspecification
might have negatively affected the efficiency of the fixed
effect estimates but not their consistency [17,23].
Estimation of the Cook’s distance on the full set of
covariates showed that only o n ep h a r m a c ym a r g i n a l l y
exceeded the cut-off point. No significant differences on
the fixed effect estimates however were observed after
re-estimation of the model on data that excluded any
prescriptions from this specific pharmacy. Furthermore,
after the re-estimations the new variance of the phar-
macy-related random effect term was significantly smal-
ler and there was no evidence to reject the assumption
of normality through the SW test. Finally, the Somers
Dxycriterion gave evidence of a very good fit for the
model (Dxy = 0.985).
GLMM results for branded substitution
As far as the branded substitution is concerned (also
shown in Table 3), results that generally mirrored those
for generic substitution were found. In particular, a high
proportion of prior brand use (b’s ranging from 2.968 to
5.809, with P < 0.001 in both cases) as well as whether
the patient is dispensed a prescription for the specific
drug class for the first time (b =2 . 7 5 2 ,P < 0.001) were
found to be positively related with the probability of
branded substitution. Oppositely, the distance from
patent expiry (b = -0.046, P < 0.001) as well as whether
the dispensing pharmacy belongs to a chain (b = -0.605,
P < 0.001) or a partnership (b = -1.752, P < 0.001) were
found to be negatively related to the probability of
branded substitution. Generic antidepressant and PPI
p r e s c r i p t i o n sw e r em o r el i k e l yt ob es u b s t i t u t e dw i t ha
Table 2 Summary of linked prescriptions (pharmacy and GP database) for the two analyses: branded prescriptions
that can be potentially substituted generically (generic substitution analysis) and generic prescriptions that can be
potentially substituted by a branded product (branded substitution analysis)
Generic substitution analysis Branded substitution analysis
No. of linked prescriptions 17,204 36,695
No. of prescriptions (%) on:
￿ ACE inhibitors 6,068 (35.27) 10,259 (27.96)
￿ Antidepressants 4,626 (26.9) 11,760 (32.04)
￿ PPIs 3,788 (22.03) 8,187 (22.32)
￿ Statins 2,721 (15.81) 6,491 (17.68)
Average prescription- delivery lag in days (SD) 0.48 (0.84) 0.41 (0.91)
Average duration after patent expiry in months (SD) 27.47 (12.83) 35.07 (19.84)
No. of pharmacies 26 26
Individual pharmacy
a 18 19
Pharmacy in a partnership
a 89
Pharmacy in a chain
a 57
No. sample patients 1,423 3,855
Female patients (%) 819 (57.6) 2,215 (57.5)
Average age in years (SD) 61.05 (15.15) 57.96 (16.6)
a Pharmacy ownership status can vary over time for each pharmacy.
SD = standard deviation.
Pechlivanoglou et al. BMC Health Services Research 2011, 11:89
http://www.biomedcentral.com/1472-6963/11/89
Page 5 of 9branded drug in comparison to ACE inhibitor prescrip-
tions (b = 1.846, P < 0.001 and b = 0.986, P < 0.001,
respectively). The opposite was found for statin prescrip-
tions (b = -0.634, P < 0.001).
Again, the LRTs showed evidence of significant het-
erogeneity in the probability of branded substitution
within patients and pharmacies. Cook’sd i s t a n c e sd i d
not exceed the cut off point for any pharmacy or patient
and the SW test found no evidence to reject the hypoth-
esis of normality for the pharmacy random effect terms
(SW test P = 0.627). However, the normality hypothesis
for the patient random effects was rejected (SW test P <
0.001). Again, our results are likely to be conservative in
terms of significance due to this violation, but not
biased in terms of effect size [17,23].
Based on the Somers Dxy criterion, the model fitted very
adequately to the branded substitution data (Dxy = 0.981).
Discussion
In this study we analyzed the route of a prescription,
from the moment of a treatment decision by the GP to
the drug delivery by the pharmacist, with a specific
interest in generic and branded substitution. In particu-
lar, we analyzed the behaviour of the pharmacist with
regard to generic and branded substitution by using
information related to patients’ and pharmacists’ charac-
teristics and the specific timing of the prescriptions and
deliveries. For this purpose, prescription-level informa-
tion from both a GPs’ and a pharmacies’ database was
merged.
We found that two of every three prescriptions were gen-
erically prescribed by the GP, while for 32% of the prescrip-
tions the GPs prescribed the branded drug. The relatively
high proportion of prescriptions written using the brand
name could possibly indicate the effect of pharmaceutical
detailing and marketing efforts and routine prescribing of
branded drugs by the GPs [24]. We are currently directing
one of the further researches into this aspect.
Following the prescription until delivery of the drug by
the pharmacist, we noticed that generic substitution
occurs in 8% of the total prescriptions (25% of the branded
prescriptions), only marginally more often than branded
Table 3 Estimates of the generalized linear mixed models on the probability of generic and branded substitution
Generic substitution Branded substitution
Log Odds (b) P-value Log Odds (b) P-value
Fixed effects estimates
Intercept 4.262 < 0.001 -6.978 < 0.001
Prescriptions to female patients -0.163 0.284 0.095 0.391
First prescription in the drug class -2.582 < 0.001 2.752 < 0.001
Prescription history 0.076 < 0.001 0.016 0.361
Branded ratio
Branded ratio [0 - 0.33) baseline
Branded ratio [0.33 - 0.66) -3.210 < 0.001 2.960 < 0.001
Branded ratio [0.66 - 1] -5.952 < 0.001 5.809 < 0.001
Pharmacy property status
Individually owned pharmacy baseline
Pharmacy in a partnership 0.954 0.046 -1.752 < 0.001
Pharmacy in a chain 0.687 < 0.001 -0.605 < 0.001
Duration after patent expiry (months) -0.011 0.002 -0.046 < 0.001
Age
Age [16-31] baseline
Age (31-46] 0.568 < 0.007 -0.399 0.038
Age (46-52] 0.546 0.012 -0.146 0.307
Age (52-88] 0.474 0.028 -0.153 0.262
Drug group
ACE Inhibitors baseline
Antidepressants -0.579 0.004 1.846 < 0.001
PPIs -1.085 < 0.001 0.986 < 0.001
Statins 0.574 0.001 -0.634 < 0.001
Random effects estimates
Pharmacy-level residual variance 1.915 0.350
Patient- level residual variance 2.346 1.879
Somers Dxy criterion 0.985 0.981
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generic prescriptions). We estimated generalized linear
mixed models (GLMMs) for both types of substitution in
an effort to identify the characteristics that may lead the
pharmacist towards generic or branded substitution.
Application of the GLMMs yielded results regarding dura-
tion from patent expiry that were in accordance with prior
studies [7,25].
In particular, the probability of generic substitution for
a prescription was found to be significantly and posi-
tively related to the experience of the patient on the use
of drugs of the same drug class but negatively related to
the proportion of prior branded use in this drug class.
Obviously, it is less likely for a patient who has routinely
been delivered the branded drug in the past, and is
again prescribed a branded, to have his prescription gen-
erically substituted by the pharmacist. The opposite
holds true for the case of branded substitution where
prior branded use seems to positively affect the prob-
ability of branded substitution. In the case of the first
prescription for any user, pharmacists seem to be more
reluctant regarding generic substitution. The pharmacist,
possibly following the patients’ perception that branded
drugs are generally safer and more effective, prefers to
either deliver a branded prescription or even substitute
a generic one with the branded.
The higher likelihood for both generic and branded
substitution close to the time of patent expiry can possi-
bly be explained by the dynamic process of generic dif-
fusion. After the patent expiry date, GPs may still
prescribe the branded drug but the stock of the pharma-
cist might already be replaced with generic alternatives,
enhancing the impetus for generic substitution. Oppo-
sitely, the generic might be prescribed while there is still
branded stock available and/or lack of information in
the pharmacy regarding the existence, efficacy and safety
of generic alternatives. In general, we notice that substi-
tution by the pharmacist is very much concentrated in
the period where the generic drug starts diffusing in the
market.
The lower probability for branded substitution, in
combination with the higher probability of generic sub-
stitution of prescriptions dispensed by pharmacies
belonging to a chain or a partnership might be related
to the fact that these organizations have a stricter policy
as well as additional incentives towards generic use [26].
Also, bulk orders of generic drugs by chain pharmacies
may result in higher discounts from the generic manu-
facturers and, hence, into lower generic acquisition costs
[27].
Finally, differences were identified between substitution
patterns of different drug groups. Antidepressants and
PPIs were found to be less often generically substituted
and more frequently substituted from generic alternative
to branded, compared to ACE inhibitors and statins. The
reduced probability for the class of antidepressants could
possibly be attributed to concerns of patients on the
effectiveness of the generic alternative. Furthermore, the
patient expiry of the branded version of paroxetine was
followed by specific patent extensions and legal battles
from the producing pharmaceutical company in order to
maintain the branded market share with a potentially
substantial effect on substitution patterns [28]. A similar
cause might be attributed to the lower probability of gen-
eric substitution on PPIs. The branded manufacturer of
omeprazole introduced a new formulation of the drug
that, in combination with extensive marketing efforts,
maintained a large share of the omeprazole market [29].
Furthermore, concerns have been raised on the in vitro
dissolution profile and kinetic properties of generic ome-
prazole compared to the branded drug [30].
Through the application of a GLMM approach, we
detected a significant amount of heterogeneity in the beha-
viour of pharmacists towards, mainly generic, substitution.
Except from the analysed characteristic of the pharmacy
status, which was available to us, specific location and
competition factors may be expected to additionally influ-
ence the decision of the pharmacist on substitution. A
pharmacy in a more remote district which might enjoy a
certain monopoly on drug distribution over the area will
possibly be more inclined to substitution if this is finan-
cial-economically attractive. Oppositely, pharmacy compe-
tition within a single city might oblige pharmacists to be
more elastic towards specific patient requests, for example,
regarding preferences for staying on the branded product
with which potentially a lot of experience already exists.
Also, no information on potential discounts achieved by
pharmacies and other financial benefits that might co-
determine pharmacists’ behaviour were available to us.
There was also considerable evidence found regarding the
unobserved variation in the substitution probability
among different patients. This was expected since patients
behave differently when confronted with the decision of
substitution, depending on characteristics that are impos-
sible to be identified through our dataset such as tolerabil-
i t yo ft h eg e n e r i ca l t e r n a t i v e , existence of comorbidities
and attitudes towards drug use. Such heterogeneity in
behaviour of pharmacists and patients, potentially related
to above mentioned factors unobserved in our database,
provides a strong rationale to use the random effects
model as we did here.
To our knowledge, this is the first paper that describes
the extent and nature of generic and branded substitu-
tion by pharmacists in the Netherlands. Our efforts to
explicitly identify factors that might affect the likelihood
of these substitutions may help in designing specific stra-
tegies to achieve general goals in this area, often concern-
ing the increase of generic and discouragement of
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Page 7 of 9branded substitution. In respect, our findings indicate
that policies enhancing generic substitution could be tar-
geted to increase generic use at first prescription, for
those patients with a long history on the branded drug,
the relatively young patients and in individually-owned
pharmacies. As these aspects are mirrored in our analysis
on branded substitution, the same types of prescriptions,
patient groups and pharmacies should be targeted for
discouraging branded substitution. Explicit information
on safety and efficacy of the generic PPIs and antidepres-
sants could help raising levels of generic substitution
(decreasing levels of branded substitution) to levels
achieved for the other drug groups investigated namely
of statins and ACE-inhibitors.
One caveat in our analysis is the lack of information
concerning the capability of the pharmacist to dispense
the generic drug instead of the branded, as some of the
prescriptions explicitly indicate that generic substitution
should not be performed. Another important factor of
influence on which our databases offer no information
is the monetary incentives that pharmacists are offered,
most often in the form of discounts, from the pharma-
ceutical industry. Given that generic manufacturers have
been evidently found to offer greater discounts than
branded manufacturers [5,31] it could however be
hypothesized that the presence of discounts results into
higher generic substitution levels, yet the data to actu-
ally analyse this currently lack us.
Furthermore, despite the use of a mixed model to cor-
rect for unobserved heterogeneity, we might still lack
important information on other potential explanatory
variables such as pharmacy stock sizes, regional insur-
ance companies’ rules and incentives for substitution (e.
g. preference policy) and the intensity of detailing.
Further research is directed towards providing more
insight regarding these yet “unobserved” variables.
Another interesting extension of the current research
would be an analysis on the effect of patent expiry on
therapeutic substitution. Although Klok et.al [30] have
already identified a positive effect of the patent expiry of
branded omeprazole on therapeutic substitution within
the PPI group, investigation in a larger number of drug
classes would give a more general impression of the
effect of patent expiries on therapeutic substitution.
Conclusions
Overall our findings suggest that even though generic
delivery is strongly connected to generic prescribing, the
event of generic substitution, when it occurs, is mainly
affected by the type of the pharmacy ownership, the timing
of the prescription, the type of the drug and the patient’s
age and experience with the drug. The development of
policies to further contain Dutch drug costs, using generic
substitution as an instrument for this, could benefit from
this knowledge, for example, by specifically targeting types
of pharmacies, patients or drug classes.
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